Počet záznamů: 1
In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles
- 1.
SYSNO ASEP 0601735 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název In vitro and in vivo study of 221Fr and 213Bi progeny release from the 225Ac-labelled TiO2 nanoparticles Tvůrce(i) Sakmár, M. (CZ)
Kozempel, J. (CZ)
Kučka, Jan (UMCH-V) RID, ORCID
Janská, T. (CZ)
Štíbr, M. (CZ)
Ondrák, L. (CZ)
Ondrák Fialová, K. (CZ)
Vlk, M. (CZ)
Šefc, L. (CZ)
Bruchertseifer, F. (DE)
Morgenstern, A. (DE)Číslo článku 108973 Zdroj.dok. Nuclear Medicine and Biology. - : Elsevier - ISSN 0969-8051
140-141, January-February (2025)Poč.str. 8 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova targeted alpha therapy ; actinium-225 ; bismuth-213 Vědní obor RIV JJ - Ostatní materiály Obor OECD Nano-materials (production and properties) CEP TO01000074 GA TA ČR - Technologická agentura ČR Výzkumná infrastruktura Czech-BioImaging III - 90250 - Ústav molekulární genetiky AV ČR, v. v. i. Způsob publikování Omezený přístup Institucionální podpora UMCH-V - RVO:61389013 UT WOS 001364696400001 EID SCOPUS 85209681143 DOI https://doi.org/10.1016/j.nucmedbio.2024.108973 Anotace Targeted alpha therapy (TAT) is an effective option for cancer treatment. To maximize its efficacy and minimize side effects, carriers must deliver radionuclides to target tissues. Most of the nuclides used in TAT decay via the alpha cascade, producing several radioactive daughter nuclei with sufficient energy to escape from the original carrier. Therefore, studying these daughter atoms is crucial in the search for new carriers. Nanoparticles have potential as carriers due to their structure, which can prevent the escape of daughter atoms and reduce radiation exposure to non-target tissues. This work focuses on determining the released activity of 221Fr and 213Bi resulting from the decay of 225Ac labelled TiO2 nanoparticles. Labelling of TiO2 nanoparticles has shown high sorption rates of 225Ac and its progeny, 221Fr and 213Bi, with over 92 % of activities sorbed on the nanoparticle surface for all measured radionuclides. However, in the quasi-dynamic in vitro system, the released activity of 221Fr and 213Bi is strongly dependent on the nanoparticles concentration, ranging from 15 % for a concentration of 1 mg/mL to approximately 50 % for a nanoparticle concentration of 10 μg/mL in saline solution. The released activities of 213Bi were lower, with a maximum value of around 20 % for concentrations of 0.05, 0.025, and 0.01 mg/mL. The leakage of 225Ac and its progeny was tested in various biological matrices. Minimal released activity was measured in saline at around 10 % after 48 h, while the maximum activity was measured in blood serum and plasma at 20 %. The amount of 225Ac released into the media was minimal (<3 %). The in vitro results were confirmed in a healthy mouse model. The difference in %ID/g was clearly visible immediately after dissection and again after 6 h when 213Bi reached equilibrium with 225Ac. The study verified the potential release of 225Ac progeny from the labelled TiO2 nanoparticles. Experiments were performed to determine the dependence of released activity on nanoparticle concentration and the biological environment. The results demonstrated the high stability of the prepared 225Ac@TiO2 NPs and the potential release of progeny over time. In vivo studies confirmed our hypothesis. The data obtained suggest that the daughter atoms can escape from the original carrier and follow their own biological pathways in the organism. Pracoviště Ústav makromolekulární chemie Kontakt Eva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358 Rok sběru 2026 Elektronická adresa https://www.sciencedirect.com/science/article/pii/S0969805124000994?via%3Dihub
Počet záznamů: 1